BackgroundDietary cholesterol plays an important role in the development of atherogenesis and cardiovascular diseases. We explored the prospective effect of grape seed proanthocyanidins in controlling hypercholesterolemia induced oxidative injury and apoptosis in atherogenic animals.MethodsFour groups of male Wistar rats (250–300 g) were used for the study. Group I served as control and received vehicle (saline) alone, Group II served as the induction group fed with a high-cholesterol diet (rat chow supplemented with 4% cholesterol and 1% cholic acid—CC diet) for 30 days, Group III served as drug control and was treated with grape seed proanthocyanidins (100 mg/kg body weight) orally for 30 days, and Group IV animals were fed with CC diet for 30 days along with grape seed proanthocyanidins (100 mg/kg body weight) orally.ResultsCC diet induced an abnormal increase in lipid peroxidation, tissue cholesterol, triglyceride, serum low-density lipoprotein, and very low density lipoprotein, and decreased the high-density lipoprotein concentration. Altered activity of cardiac and serum creatine kinase, accompanied by a decreased cardiac enzymatic and nonenzymatic antioxidant defense system and an increase in the expression of cytochrome c and caspases-3, was observed in CC diet-fed rats. These changes were partially restored in the grape seed proanthocyanidin-treated group.ConclusionGrape seed proanthocyanidins have cardioprotective effects against CC diet-induced hypercholesterolemia via their ability to reduce, directly or indirectly, free radicals in the myocardium. 相似文献
Objective: To assess whether the polymorphism of ERCC1 Asn118Asn (C→T) had effects on cancer response to chemotherapy and outcome in Chinese patients treated with oxaliplatin as first-line chemotherapy regimen for advanced colorectal cancer.Methods: ERCC1 Asn118Asn polymorphism was analyzed in 99 patients with stages Ⅲ and Ⅳ advanced colorectal cancer treated with oxaliplatin-based chemotherapy.For all of the patients, ERCC1 Asn118Asn genotype was analyzed for associations with treatment response and time to disease progress (TTP).Results: The allele frequencies of the ERCC1 gene codon 118 were C/C 50.51% (50/99), C/T 41.41% (41/99), T/T 8.08% (8/99), respectively.Patients with C/C genotype showed higher response rate than those with C/T T/T (OR = 3.764, 95% CI: 1.310-10.813).The median TTP of all patients was 7 months (95% CI: 5.569-8.431).Patients with C/C genotype showed a median TTP of 10 months (95% CI:8.924-11.076), which was longer than 5 months (95% CI: 4.424-5.576) in patients with C/T T/T genotypes.Conclusion:Our results showed a link between ERCC1 Asn118Asn genetic polymorphism and cancer response to oxaliplatin-based chemotherapy and time to disease progress in Chinese patients with advanced colorectal cancer.ERCC1 Asn118Asn genotyping may be of predictive benefit in selecting treatment regimen for advanced colorectal cancer. 相似文献